Orgenesis Inc. EV/FCF

EV/FCF of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of Orgenesis Inc. is -0.96 (as of December 30, 2020)
  • EV/FCF for the quarter ending June 29, 2021 was -1.46 (a -4.9% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF increased by 83.84%
  • Annual EV/FCF for 2020 was -0.96 (a -72.06% decrease from previous year)
  • Annual EV/FCF for 2019 was -3.42 (a 50.07% increase from previous year)
  • Annual EV/FCF for 2018 was -2.28 (a -42.42% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Orgenesis Inc.

Most recent EV/FCFof ORGS including historical data for past 10 years.

Interactive Chart of EV/FCF of Orgenesis Inc.

Orgenesis Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -1.46 -1.54
2020 -0.96 -0.8 -1.15 0.84 -0.96
2019 -3.42 -3.21 -2.59 -2.75 -3.42
2018 -2.28 -4.11 -8.1 -149.09 -2.28
2017 20.91 24.24 35.13 26.1
2016 12.99 -7.59 -5.49 -1.21 12.99
2015 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.